Navigation Links
JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
Date:6/20/2013

s partnership will accelerate LATITUDE's stable, soluble glucagon formulation and its potential for new medical applications. Our partnership with JDRF will give us an opportunity to provide a missing piece needed to make the bi-hormonal artificial pancreas a reality."

Both Xeris and LPI are using approaches distinct from the ongoing JDRF-supported research program led by W. Kenneth Ward, M.D. at OHSU, which is utilizing a liquid solution of glucagon at a high pH in order to stabilize the drug.

Said Dr. Dutta: "We are excited to explore whether the novel glucagon formulations by Xeris and LATITUDE could prove effective for use in an infusion pump, thereby bringing us closer to the future of closed loop artificial pancreas systems by 'resetting' the missing hormonal balance in people with type 1 diabetes."

About T1D
In T1D, a person's pancreas stops producing insulin, a hormone that enables people to get energy from food. People with T1D need to test their blood sugar and give themselves insulin (with injections or an insulin pump) multiple times every day, and carefully balance insulin doses with eating and daily activities throughout the day and night. However, insulin is not a cure for diabetes, and even with that intensive care, a significant portion of the day is still spent with either high or low blood sugar, placing people with T1D at risk for devastating complications such as heart attack, stroke, blindness, and amputation.

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to bet
'/>"/>

SOURCE JDRF
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
2. Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option
3. Haemonetics Announces Next Steps in Manufacturing Transformation
4. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
5. BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research
6. Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital
7. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
8. Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
9. Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Specialty Coating Systems Announces New Antimicrobial Parylene Technology
11. Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US announces ... leading online community and information resource for neurologists and other ... and Alzheimer disease , with discussions of the latest ... 1 million Americans have Parkinson disease , more than the ... Lou Gehrig disease. Diagnosis can be difficult because ...
(Date:10/17/2014)... Oct. 17, 2014 Research and ... "Research and Development Prospect of China Dialysis Market, ... Based on the 2013 version, this update ... about dialysis industry and the relevant effect in ... dialysis industry segmentations. Moreover, it analyzes Chinese private-owned ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... WAILEA, Hawaii and SUNNYVALE, Calif., June 27, ... from two open-label, multi-center Phase 2,clinical trials ... Injection, the company's lead product,candidate, in combination ... (docetaxel) as a second-line treatment,for patients with ...
... WIRE)--Jun 27, 2007 - Columbia,Laboratories, Inc. (NASDAQ: ... multi-dose pharmacokinetic study of,vaginally-administered lidocaine, which the ... This 42-subject study was designed to provide ... bioadhesive vaginal lidocaine,formulation at three dose strengths ...
Cached Medicine Technology:Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 2Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 3
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 National ... Ohio Chapter of the American Academy of Pediatrics (Ohio AAP, ... Administration (NHTSA) in encouraging parents of teen drivers to talk ... hit the road. , Motor vehicle crashes are the leading ... 2,055 teen drivers involved in fatal crashes, and 859 (42%) ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... that the public will use performance data to choose their ... a paper published on bmj.com today, two experts ... choice is not at present a strong lever for change, ... improved to optimise its effect. Research conducted over the ...
... HealthDay Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- ... of heartburn drugs while they were pregnant did not ... a large Danish study finds. This class of ... as Prilosec (omeprazole), Prevacid (lansoprazole) and Nexium (esomeprazole). All ...
... 24 (HealthDay News) -- Excessive alcohol consumption -- a common ... injury and death, warns the American College of Emergency Physicians ... when they get together with family and friends. "Very ... suffer the loss of a loved one because of an ...
... , WEDNESDAY, Nov. 24 (HealthDay News) -- Parents ... if they,re traveling during the holiday season, an expert warns. ... you can,t plan for everything, being prepared will help keep ... Cahill, an associate professor of pediatrics at Loyola University Chicago ...
... WEDNESDAY, Nov. 24 (HealthDay News) -- A study conducted ... for blacks than it is for whites. In fact, ... one-fifth higher than it is for whites in that state. ... on Smoking and Health at the U.S. Centers for Disease ...
... Americans get ready to travel to holiday gatherings with family and ... them are reminded that there are some things you need to ... pack a copy of all vaccination records so that you can ... those records if you board your pet while going on an ...
Cached Medicine News:Health News:Experts question whether patients will use performance data to choose their care 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 3Health News:Holiday Drinking Can Kill, Experts Warn 2Health News:Preparation Can Help Kids With Nut Allergies Travel Safely 2Health News:Black Smokers May Face Higher Death Risk Than Whites: CDC 2
Claes Shielded Retinotomy Scissors, Vertical...
... DxSelect is intended for qualitatively detecting antibodies ... serum. The test is indicated for testing ... an aid in the presumptive laboratory diagnosis ... intended for self-testing, and this test is ...
... Indirect immunofluorescent antibody (IFA) test for ... IgG antibodies to St. Louis Encephalitis virus ... Equine Encephalitis virus (EEE), and California Encephalitis/La ... 8-well slides with fixed individual spots of ...
... immunofluorescent antibody (IFA) test ... semi-quantitation of human serum ... viral capsid antigen (VCA). ... 12-well slides, FITC IgG ...
Medicine Products: